Simon H. Stertzer
Independent DirectorDr. Simon H. Stertzer, M.D., FACC, FAHA, FACP has been Chairman of the Board of Medlogics Device Corporation since September 2004. Dr. Stertzer has been Member of Medical Advisory Board at Avenda Health Inc. Dr. Stertzer served as Scientific Advisor for Helix Biotherapeutic Delivery Systems at Biocardia, Inc. He is managing member of Windrock Enterprises, LLC, a real estate investment company, since May 1999. He had served as a Director of Frontiere Algorithmic Design LLC, a software development company, from June 2014 till October 2020. He also serves as Director of AIVA App Limited Liability Company from June 2014 to October 2020. Dr. Stertzer serves as Director of Experimental Angioplasty, Clinical Professor of Medicine, Emeritus and Associate Director of International Medical Services at Stanford University School of Medicine, Division of Cardiovascular Medicine. He was appointed Professor of Medicine at Stanford University in 1998 and became Professor Emeritus at Stanford University in 2011. Dr. Stertzer serves on the medical advisory board of Avenda Health, a private prostate cancer therapy company and was appointed in June 2019. He served as Assistant Resident in Medicine at NYU and later as Chief Medical Resident at NYU Division of Bellevue Hospital. His numerous academic and hospital appointments include Attending Cardiologist at NYU School of Medicine from 1965 to 1983, Chief of the Hemodynamics Laboratory at Lenox Hill Hospital New York from 1971 to 1983 and Director of Medical Research, San Francisco Heart Institute, Seton Medical Center, Daly City, CA, from 1983 to 1992. He was a founder of numerous medical technology companies, including Arterial Vascular Engineering which was acquired by Medtronic, Quanum Medical which was acquired by Boston Scientific and Vascular Science, Inc. which was acquired by St. Jude Medical. He serves as an Independent Director of Biocardia, Inc. since 2002 and served as its Chairman until 2020. He served as Director of Pathway Medical Technologies, Inc. He has written, lectured and taught extensively about such new technologies as: Treatment of acute heart attacks with angioplasty, High speed Rotational Atherectomy, Stent treatment of Coronary Disease, Pacemaker Therapy and Drug eluting devices for coronary restenosis. He had a fellowship at NYU Hospital in Cardiovascular Disease. Dr. Stertzer received his MD from the New York University and interned in surgery at the University of California Hospitals, San Francisco. He also earned a Certificat de Physiologie from University of Paris (Sorbonne) and had a fellowship at New York University Hospital in Cardiovascular Disease. Dr. Stertzer received a Bachelor of Arts degree in Humanities from Union College.
Positions
- Company NameBioCardia, Inc.Stock CodeBCDAPositionIndependent DirectorColleagues
